KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma

Oncology Reports

Volumn 17, Issue 4, 2007, Pages 737-741

  Tang, Wei ^a,b   Guo, Qian ^a   Qu, Xianjun ^a,b   Inagaki, Yoshinori ^c   Seyama, Yasuji ^a   Midorikawa, Yutaka ^a   Gai, Ruoyan ^a   Kokudo, Norihiro ^a   Sugawara, Yasuhiko ^a   Nakata, Munehiro ^c   Makuuchi, Masatoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SHANDONG UNIVERSITY   (China)

^c TOKAI UNIVERSITY   (Japan)

Author keywords

Cholangiocarcinoma; Hepatocellular carcinoma; Immunohistochemistry; KL 6 mucin; Liver cancer

Indexed keywords

CYTOKERATIN 7; MUC1 PROTEIN, HUMAN; MUCIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUCINS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249937240     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.4.737     Document Type: Article

References (21)

1. The Liver Cancer Study Group of Japan: Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 211: 277-287, 1990.
2. Allen RA and Lisa JR: Combined liver cell and bile duct carcinoma. Am J Pathol 25: 647-655, 1949.
3. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA and Rabin L: Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 55: 124-135, 1985. (Pubitemid 15198209)
4. Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, DeMatteo RP, Blumgart LH and Klimstra D: Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94: 2040-2046, 2002. (Pubitemid 34270058)
5. Kohno N: Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 46: 151-158, 1999.
6. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K and Yamakido M: Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 18: 203-216, 1988.
7. Tang W, Inagaki Y, Kokudo N, Guo Q, Seyama Y, Nakata M, Imamura H, Sano K, Sugawara Y and Makuuchi M: Aberrant expression of KL-6 in carcinoma of the ampulla of Vater: association with cancer progression. World J Gastroenterol 11: 5450-5454, 2005. (Pubitemid 41684701)
8. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H and Makuuchi M: Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol 12: 54-59, 2006. (Pubitemid 43126083)
9. Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 2nd edition. Kanehara, Tokyo, 2003.
10. Sobin LH and Wittekind C: TNM Classification of Malignant Tumors. 5th edition. Wiley-Liss, New York, 1997.
11. Maeda T, Adachi E, Kajiyama K, Sugimachi K and Tsuneyoshi M: Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathological features. Human Pathol 26: 956-964, 1995.
12. Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, Imai K and Yonezawa S: MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 39: 220-229, 2004. (Pubitemid 38461485)
13. Wee A: Fine needle aspiration biopsy of the liver: algorithmic approach and current issues in the diagnosis of hepatocellular carcinoma. Cyto J 2: 7, 2005.
14. Vessey CJ and de la Hall PM: Hepatic stem cells: a review. Pathology 33: 130-141, 2001. (Pubitemid 32453403)
15. Moll R, Franke WW, Schiller DL, Geiger B and Krepler R: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24, 1982. (Pubitemid 13215192)
16. Maeda T, Kajiyama K, Adachi E, Takenaka K, Sugimachi K and Tsuneyoshi M: The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol 9: 901-909, 1996. (Pubitemid 26319720)
17. Centeno BA: Pathology of liver metastasis. Cancer Control 13: 13-26, 2006.
18. Sasaki M, Nakanuma Y and Kim YS: Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: an immunohistochemical study. Hepatology 24: 1074-1078, 1996. (Pubitemid 26365906)
19. Higashi M, Yonezawa S, Ho JJL, Tanaka S, Irimura T, Kim YS and Sato E: Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 30: 1347-1355, 1999.
20. Matsumura N, Yamamoto M, Aruga A, Takasaki K and Nakano M: Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer 94: 1770-1776, 2002. (Pubitemid 34241116)
21. Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W and Zhang YQ: Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol 11: 4661-4666, 2005. (Pubitemid 41179519)